Royalty Pharma (RPD) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RPD Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Royalty

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RPD Stock 12 Month Forecast

Average Price Target

€56.88

▲(10.85% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is €56.88 with a high forecast of €60.63 and a low forecast of €53.70. The average price target represents a 10.85% change from the last price of €51.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","61":"€61","36.25":"€36.3","44.5":"€44.5","52.75":"€52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60.6284224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.87523434666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€56.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.69945984,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€53.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,36.25,44.5,52.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.73141710769231,52.472834215384616,53.21425132307692,53.95566843076923,54.697085538461536,55.43850264615385,56.17991975384615,56.921336861538464,57.66275396923077,58.40417107692308,59.145588184615384,59.88700529230769,{"y":60.6284224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.44271033435898,51.895420668717954,52.34813100307693,52.8008413374359,53.253551671794874,53.70626200615385,54.158972340512825,54.6116826748718,55.06439300923078,55.51710334358975,55.96981367794872,56.4225240123077,{"y":56.87523434666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.19841998769231,51.40683997538462,51.61525996307692,51.82367995076923,52.03209993846154,52.24051992615385,52.448939913846154,52.65735990153846,52.86577988923077,53.07419987692308,53.282619864615384,53.49103985230769,{"y":53.69945984,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.755,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.961,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.636,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.211,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.201,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.508,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.043,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.596,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.328,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.453,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.775,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€60.63

Average Price Target€56.88

Lowest Price Target€53.70

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ashwani Verma

UBS

€50.23→€57.16

Buy

11.41%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (NASDAQ: RPRX), BridgeBio Pharma (NASDAQ: BBIO) and NanoViricides (NYSE MKT: NNVC)

Chris Schott

J.P. Morgan

€53.7

Buy

4.66%

Upside

Reiterated

08/10/26

J.P. Morgan Keeps Their Buy Rating on Royalty Pharma (RPRX)

Geoff Meacham

Citi

€57.16→€60.63

Buy

18.16%

Upside

Reiterated

08/06/26

Royalty Pharma price target raised to $70 from $66 at CitiRoyalty Pharma price target raised to $70 from $66 at Citi

Terence Flynn

Morgan Stanley

€55.43→€56.3

Buy

9.72%

Upside

Assigned

08/06/26

Royalty Pharma (RPRX) Receives a Buy from Morgan Stanley

Asad Haider

Goldman Sachs

€51.1→€57.16

Buy

11.41%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Royalty Pharma (NASDAQ: RPRX) and Urogen Pharma (NASDAQ: URGN)

Michael Nedelcovych

TD Cowen

€43.31→€56.3

Buy

9.72%

Upside

Reiterated

07/13/26

Royalty Pharma price target raised to $65 from $50 at TD CowenRoyalty Pharma price target raised to $65 from $50 at TD Cowen

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

07/10/26

Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ashwani Verma

UBS

€50.23→€57.16

Buy

11.41%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (NASDAQ: RPRX), BridgeBio Pharma (NASDAQ: BBIO) and NanoViricides (NYSE MKT: NNVC)

Chris Schott

J.P. Morgan

€53.7

Buy

4.66%

Upside

Reiterated

08/10/26

J.P. Morgan Keeps Their Buy Rating on Royalty Pharma (RPRX)

Geoff Meacham

Citi

€57.16→€60.63

Buy

18.16%

Upside

Reiterated

08/06/26

Royalty Pharma price target raised to $70 from $66 at CitiRoyalty Pharma price target raised to $70 from $66 at Citi

Terence Flynn

Morgan Stanley

€55.43→€56.3

Buy

9.72%

Upside

Assigned

08/06/26

Royalty Pharma (RPRX) Receives a Buy from Morgan Stanley

Asad Haider

Goldman Sachs

€51.1→€57.16

Buy

11.41%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Royalty Pharma (NASDAQ: RPRX) and Urogen Pharma (NASDAQ: URGN)

Michael Nedelcovych

TD Cowen

€43.31→€56.3

Buy

9.72%

Upside

Reiterated

07/13/26

Royalty Pharma price target raised to $65 from $50 at TD CowenRoyalty Pharma price target raised to $65 from $50 at TD Cowen

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

07/10/26

Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Royalty Pharma

3 Months

Geoff MeachamCiti

Success Rate

16/22 ratings generated profit

Average Return

+4.03%

Copying Geoff Meacham's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +4.03% per trade.

1 Year

Geoff MeachamCiti

Success Rate

15/22 ratings generated profit

Average Return

+19.40%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +19.40% per trade.

2 Years

Geoff MeachamCiti

Success Rate

18/22 ratings generated profit

Average Return

+42.16%

Copying Geoff Meacham's trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +42.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RPD Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RPD has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RPD average Analyst price target in the past 3 months is 56.88.

Each month's total comprises the sum of three months' worth of ratings.

RPD Financial Forecast

RPD Earnings Forecast

Next quarter’s earnings estimate for RPD is €1.01 with a range of €0.99 to €1.05. The previous quarter’s EPS was €1.14. RPD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RPD has Performed in-line its overall industry.

RPD Sales Forecast

Next quarter’s sales forecast for RPD is €759.91M with a range of €740.65M to €772.18M. The previous quarter’s sales results were €583.89M. RPD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RPD has Performed in-line its overall industry.

RPD Stock Forecast FAQ

What is DE:RPD’s average 12-month price target, according to analysts?

Based on analyst ratings, Royalty Pharma PLC’s 12-month average price target is 56.88.

What is DE:RPD’s upside potential, based on the analysts’ average price target?

Royalty Pharma PLC has 10.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Royalty Pharma PLC a Buy, Sell or Hold?

Royalty Pharma PLC has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Royalty Pharma PLC’s share price target?

The average share price target for Royalty Pharma PLC is 56.88. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €60.63 ,and the lowest forecast is €53.70. The average share price target represents 10.85% Increase from the current price of €51.31.

What do analysts say about Royalty Pharma PLC?

Royalty Pharma PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Royalty Pharma PLC?

To buy shares of DE:RPD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Royalty Pharma (RPD) Stock Forecast & Price Target

RPD Analyst Ratings

RPD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Royalty Pharma

RPD Analyst Recommendation Trends

RPD Financial Forecast

RPD Earnings Forecast

RPD Sales Forecast

RPD Stock Forecast FAQ

Detailed List of Analyst Forecasts